VisionGate Raises $2M, Partners on Technology for Lung Cancer Testing | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – VisionGate today announced it has raised $1.96 million in the first tranche of a financing round and forged two collaborations to evaluate its automated 3D cell imaging platform for the early detection of lung cancer.

The $1.96 million tranche is part of a targeted $3 million equity round and will be used for further clinical development of its technology. Participants included undisclosed new and existing investors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.